Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: Preliminary results in clinical practice - 06/05/10


Summary |
Purpose |
Our aim was to compare perfusion magnetic resonance imaging (MRI) and positron emission tomography (PET) using carbon-11 labelled methionine (MET) in gliomas and their value in differentiating tumour recurrence from necrosis.
Materials and methods |
We retrospectively reviewed 28 patients with a high-grade glioma. A total of 33MR perfusions and MET-PET were ultimately analysable for comparison between the relative cerebral blood volume (rCBV) and MET-PET examinations. Intra- and interobserver reproducibility was assessed and diagnostic value of rCBV compared to MET-PET and histology was assessed by the area under the receiver operating characteristic (ROC) curve.
Results |
ROC curve analysis showed that rCBV had at least equal performances in differentiating tumour recurrence and necrosis than MET-PET. Cut-off value of rCBV for differentiating tumour from necrosis was 182% with a sensitivity of 81.5% and a specificity of 100%.
Conclusion |
In clinical practice, perfusion MRI could replace MET-PET for differentiating necrosis from tumour recurrence.
Le texte complet de cet article est disponible en PDF.Keywords : Perfusion MRI, Methionine, PET, Glioma
Plan
Vol 37 - N° 2
P. 89-97 - mai 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.